Trump announces trade deal with EU following months of negotiations
Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions Inc. (NASDAQ:BLFS), a company with a market capitalization of $1.17 billion and a "Good" financial health rating according to InvestingPro, recently sold 284 shares of the company’s common stock, according to a recent SEC filing. The transaction, executed on March 3, 2025, was made at a price of $25.46 per share, amounting to a total value of $7,230. The stock, which has shown significant volatility and gained nearly 46% over the past year, currently trades at $26.25. Following this sale, Aebersold holds 59,907 shares directly. The transaction was conducted under a Rule 10b5-1 trading plan, which was established to manage tax withholding obligations related to the vesting of restricted stock. For deeper insights into insider trading patterns and comprehensive analysis of BLFS, including 6 additional key ProTips and detailed Fair Value calculations, visit InvestingPro.
In other recent news, BioLife Solutions reported fourth-quarter financial results that exceeded expectations, with revenues reaching $22.7 million, slightly above the consensus forecast of $22.03 million. The company posted a narrower-than-anticipated adjusted net loss of $0.04 per share, surpassing analyst estimates of a $0.08 per share loss. A significant driver of this performance was a 31% year-over-year increase in cell processing revenue, which rose to $20.3 million. BioLife Solutions has now achieved five consecutive quarters of revenue growth in its cell processing segment, which includes its core biopreservation media products.
The company also issued an optimistic financial outlook for the upcoming year, projecting revenue growth between 16% and 20% and improved operating margins. Looking further ahead, BioLife Solutions expects 2025 revenue to be between $95.5 million and $99 million, surpassing the analyst consensus of $95.45 million. The Cell Processing segment is forecasted to grow by 18-21% to reach $86.5-$89 million. Benchmark has maintained a Buy rating on BioLife Solutions, with a price target of $30, citing the company’s strong earnings forecasts and growth potential. BioLife Solutions’ biopreservation media is currently embedded in 17 approved cell and gene therapies, with eight additional approvals or expansions expected within the next 12 months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.